![](images/null.gif) |
![](images/null.gif) |
![](images/null.gif) |
|
Evaluation of lead HIV-1 vaccine regimen in APPROACH:
Phase 1/2a study testing heterologous prime boost regimens using mosaic Ad26 and MVA vectors combined with Env protein
|
|
|
Reported by Jules Levin
9th IAS Conference on HIV Science (IAS 2017), July 23-26, 2017, Paris
Hanneke Schuitemaker
VP, Head Viral Vaccine Discovery and Translational Medicine, Janssen Vaccines and Prevention B.V.
Professor in Virology at the Academic Medical Center, University of Amsterdam
IAS | Paris, 24 July 2017
![IAS1](../images/072417/072417-17/IAS1.gif)
![IAS2](../images/072417/072417-17/IAS2.gif)
![IAS3](../images/072417/072417-17/IAS3.gif)
![IAS4](../images/072417/072417-17/IAS4.gif)
![IAS5](../images/072417/072417-17/IAS5.gif)
![IAS6](../images/072417/072417-17/IAS6.gif)
![IAS7](../images/072417/072417-17/IAS7.gif)
![IAS8](../images/072417/072417-17/IAS8.gif)
![IAS9](../images/072417/072417-17/IAS9.gif)
![IAS10](../images/072417/072417-17/IAS10.gif)
![IAS11](../images/072417/072417-17/IAS11.gif)
|
|
|
![](images/null.gif) |
![](images/null.gif) |
|
|